Iovance Biotherapeutics Inc Stock Nasdaq
Equities
US53619R1023
Biotechnology & Medical Research
Sales 2024 * | 153M 208M | Sales 2025 * | 428M 584M | Capitalization | 2.9B 3.95B |
---|---|---|---|---|---|
Net income 2024 * | -356M -485M | Net income 2025 * | -199M -271M | EV / Sales 2024 * | 18.5 x |
Net cash position 2024 * | 72.44M 98.77M | Net cash position 2025 * | 144M 197M | EV / Sales 2025 * | 6.43 x |
P/E ratio 2024 * |
-7.93
x | P/E ratio 2025 * |
-15.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.57% |
Latest transcript on Iovance Biotherapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Frederick Vogt
CEO | Chief Executive Officer | 50 | 16-09-29 |
Director of Finance/CFO | 51 | 20-12-13 | |
Brian Shew
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Merrill McPeak
BRD | Director/Board Member | 88 | 11-07-19 |
Director/Board Member | 56 | 16-06-06 | |
Michael Weiser
BRD | Director/Board Member | 61 | 18-03-14 |
1st Jan change | Capi. | |
---|---|---|
-31.06% | 9.3B | |
-8.43% | 3.1B | |
-14.31% | 2.17B | |
-18.94% | 1.75B | |
+73.13% | 1.5B | |
+30.25% | 807M | |
-1.97% | 759M | |
-26.73% | 532M | |
+5.17% | 313M |